SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
SGNT was delisted on the 29th of August, 2016.
104 hedge funds and large institutions have $620M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 32 reducing their positions, and 12 closing their positions.
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
15% more capital invested
Capital invested by funds: $538M → $620M (+$82M)
13% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 32
11% more funds holding
Funds holding: 94 → 104 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$13.8M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$13.7M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.19M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.39M |
| 5 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$11.6M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$9.67M |
| 3 |
Goldman Sachs
New York
|
-$7.06M |
| 4 |
Millennium Management
New York
|
-$4.26M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$1.84M |
SGNT Hedge Fund Activity: Q2 2014 in Review
104 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q2 2014, worth a combined $620M — up 15% from $538M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SGNT positions and 12 closed out — a net gain of 10 holders — while 36 added to existing stakes and 32 trimmed.
The largest buyer was Franklin Resources, adding an estimated $13.8M. The largest seller was Citadel Advisors, cutting an estimated $11.6M.
- 104 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q2 2014, up from 94 in Q1 2014.
- Funds reported $620M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q2 2014, up 15% quarter-over-quarter.
- 22 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q2 2014 and 12 closed out, a net change of +10 holders.
- The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q2 2014 was Franklin Resources, an estimated $13.8M added.
- The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q2 2014 was Citadel Advisors, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2014.